TCRT February 2012No.1 (1-104) February 2012 ISSN 1533-0338
Intensity Modulated Radiotherapy Volumetric Response Evaluation After Intensity Modulated Radiotherapy in Patients with Supratentorial Gliomas (41-48)Radiotherapy is frequently indicated to treat cerebral gliomas. Accurate response evaluation after radiotherapy is essential to determine the efficacy of treatment. We retrospectively analyzed the volumetric tumor response after simultaneous integrated boost-intensity modulated radiotherapy (SIB-IMRT) in patients with gliomas. Thirty-five patients (Grade II, 7 patients; Grade III, 12; and Grade IV, 16) were treated with SIB-IMRT with a median total dose of 55.9 Gy/26 fractions for Grade II and 60 Gy/25 fractions for Grade III-IV tumors. Tumor responses were evaluated for enhancing volume on post-gadolinium T1-weighted images (Vgd) and hyper-intensity volume on T2-weighted FLAIR images (Vfl) on serial MRIs. With the median follow-up of 24.0 months, overall response rates (RRs) were 57% for Vgd and 51% for Vfl. Tumor grade was predictive of response favoring the lower grade in Vfl with RRs of 86% for Grade II, 75% for Grade III, and 19% for Grade IV tumors (p 5 0.004). Time to 50% or greater volume reduction (T50) in Vgd was 8 months for grade III. The T50 in Vfl was approximately 24 months both for Grade II
and III tumors. Majority of Grade IV tumors continued to progress and never reached the T50 in Vgd or Vfl. Responders survived longer than non-responders for Vgd and Vfl. Volume response after radiotherapy was dependent upon tumor grade and time. LGGs are very responsive to radiotherapy with the RRs of 86% in Vfl. The response of Vfl is more protracted compared to Vgd. Further investigation is needed to determine the clinical significance of volumetric response evaluation.
Key words: Glioma; Radiotherapy; Volume response; Survival. This article can be cited as: KH Cho, JH Choi, JY Kim, SH Lee, H Yoo, KH Shin, TH Kim, SH Moon, SH Lee, HC Park. Volumetric Response Evaluation After Intensity Modulated Radiotherapy in Patients with Supratentorial Gliomas Technol Cancer Res Treat. 11, 41-48 (2012). K. H. Cho, M.D.1*# 1Research Institute and Hospital,
National Cancer Center, Goyang,
Gyeonggi, Republic of Korea Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. |
|
Member Login | Home | Editorial Board | Instructions | Subscribe | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
|